Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

Inclusion Criteria:

• Age: 55-99 years old

• Early or intermediate AMD in at least one eye (drusen > 63 µm and/or any definitehyper- or hypopigmentary abnormalities with or without reticular pseudodrusen)

• If both eyes are eligible, both eyes will be included in the cohort study.

• Clear optical media and adequate pupillary dilation for imaging and functionaltesting.

Exclusion Criteria:

• Any surgical treatment of the eye within 3 months prior to baseline in the study eye

• History of anti-VEGF treatment in the study eye before baseline

• History of pseudophakic cystoid macular edema (Irvine Gass Syndrome) in the studyeye

• History of uncontrolled glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 25 mmHg despite treatment with IOP lowering medication), or C/D Ratio > 0.9

• Any concurrent intraocular condition in the study eye (e.g. advanced cataract ormoderate/severe diabetic retinopathy) that, in the opinion of the investigator, willmost likely require medical or surgical intervention during the study period toprevent or treat visual loss that might result from that condition

• Any concurrent intraocular condition in the study eye that, in the opinion of theinvestigator, could cause an unwanted effect on treatment efficacy, compliance orrequire intraocular surgery (except for cataract surgery and YAG capsulotomy) duringthe study period

• Presence of corneal decompensation, haze or scarring with an impact on BCVA

• Refractive error larger than 6 diopters. In case of pseudophakia or refractivesurgery: History of refractive error larger than 6 diopters.

• Intake of drugs known to cause retinal toxicity (e.g. hydroxychloroquine ortamoxifen)

• Presence of active macular neovascularization at baseline